HR 7473 · 117th Congress 2021–2023, ended

Generic Substitution Noninterference Act

Latest action · Nov 1, 2022 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedApr 7, 2022
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Generic Substitution Noninterference Act

This bill prohibits drug manufacturers from helping or directing health care providers to limit prescriptions to brand-name drugs when generic versions are available. The Federal Trade Commission and states may enforce this bill through civil actions.

Cosponsors 7

Members who signed on, in the order they did. All signed on Apr 7, 2022.

SeatCosponsorSigned on
D-RIDavid N. CicillineOriginalApr 7, 2022
D-MDJamie RaskinOriginalApr 7, 2022
D-ILJanice D. SchakowskyOriginalApr 7, 2022
D-NYJerrold NadlerOriginalApr 7, 2022
D-CAKatie PorterOriginalApr 7, 2022
D-CAMark DeSaulnierOriginalApr 7, 2022
D-VTPeter WelchOriginalApr 7, 2022

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseJudiciary Committee
Referred Apr 7, 2022
Administrative State, Regulatory Reform, and Antitrust Subcommittee
Referred Nov 1, 2022

Actions 3

Everything that happened, newest first.

  1. Nov 1, 2022Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
  2. Apr 7, 2022Introduced in House
  3. Apr 7, 2022Referred to the House Committee on the Judiciary.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article I, Section 8, Clause 18 of the Constitution of the United States (the Necessary and Proper Clause) grants Congress the power to enact this legislation.

The sponsor’s statement, as printed in the Congressional Record, vol. 168, no. 62, April 7, 2022, page H4434.

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To prohibit pharmaceutical manufacturers from interfering with therapeutically equivalent or interchangeable substitution decisions by health care providers to limit competition from a generic drug or biosimilar biological product, and for other purposes.
Short Title(s) as Introduced
Generic Substitution Noninterference Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Apr 7, 2022Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.